Core Viewpoint - The sixth batch of national centralized procurement of high-value medical consumables has been announced, covering 12 types of medical consumables in two categories, with 202 companies and 440 products selected, indicating a diverse range of product options [1] Group 1: Urological Consumables - For the first time, consumables related to urological stone surgery have been included in the centralized procurement, addressing a previous gap in this area [3] - The procurement includes key consumables needed for urological stone surgeries, such as ureteral intervention guidewires and balloon dilation catheters, with 170 companies and 398 products selected, significantly covering the main consumables required for stone surgeries [4] - The inclusion of these consumables is expected to reduce the overall treatment costs for stone diseases, which previously ranged from 20,000 to 30,000 yuan [4] Group 2: Cardiovascular Consumables - The procurement has expanded to include drug-coated balloons, enhancing treatment options for cardiovascular disease patients, complementing previously included stents [5] - A total of 32 companies and 42 products for drug-coated balloons were selected, which are well-matched with clinical usage and are expected to alleviate the financial burden on patients [5] Group 3: Procurement Rules and Impact - The procurement process has been designed to prevent "malicious low pricing" while encouraging technological innovation, ensuring that clinically recognized and capable products are selected [6] - A pricing mechanism has been established to avoid excessively low bids, using 65% of the average price of selected products as a control benchmark [6] - The national medical insurance department has successfully procured 142 types of medical consumables across nine categories, with the implementation of this procurement expected around May 2026 [6]

Core Insights - The sixth batch of national organized high-value medical consumables centralized procurement has been announced, covering 12 types of medical consumables in two categories: drug-coated balloons and urological intervention, with 202 companies and 440 products selected [1][5]. Group 1: Urological Consumables - For the first time, consumables related to urological stone surgery have been included in the centralized procurement, covering essential items such as ureteral intervention guidewires and balloons, with 170 companies and 398 products selected [3]. - This inclusion is expected to significantly reduce the overall treatment costs for stone diseases, which previously ranged from 20,000 to 30,000 yuan per procedure [3]. Group 2: Drug-Coated Balloons - The procurement now includes drug-coated balloons, expanding the coverage of cardiovascular intervention consumables, which previously included only coronary and peripheral vascular stents [5]. - The inclusion of drug-coated balloons is anticipated to benefit more patients, particularly those experiencing restenosis after stent placement [5]. Group 3: Procurement Strategy - The procurement process emphasizes a "反内卷" (anti-involution) principle, ensuring that clinically recognized and capable products are selected while preventing malicious low pricing [5][6]. - A pricing mechanism has been established to avoid excessively low bids, using the average price of selected products as a baseline for price differences [6]. - The national medical insurance department has successfully procured 142 types of medical consumables across nine categories, with the implementation expected around May 2026 [6].

Core Insights - The sixth batch of national high-value medical consumables procurement has been initiated, focusing on drug-coated balloons and urological intervention consumables, which are characterized by high clinical usage frequency and significant market demand [1][2] Group 1: Procurement Details - The procurement includes 12 types of medical consumables, with 496 products from 227 companies bidding, and 440 products from 202 companies selected, achieving an average selection rate of nearly 90% for both companies and products [2] - The market size for drug-coated balloons and urological intervention consumables prior to procurement was approximately 11 billion, with an annual procurement demand of 3.4 million units from medical institutions [2][5] - The procurement process has been optimized with new rules such as anchor pricing, second-round bidding, and revival rules, which have effectively increased the selection rate and encouraged more companies to participate at suitable prices [2][5] Group 2: Product Characteristics - Drug-coated balloons are used to improve vascular stenosis by expanding blood vessels and releasing medication, categorized into coronary and peripheral vascular balloons, complementing previously procured cardiac and peripheral vascular stents [3] - Urological intervention consumables are utilized in surgeries for kidney stones and ureteral stones, covering a wide range of products necessary for various surgical methods, addressing a previously unaddressed area in procurement [3][5] Group 3: Principles and Regulations - The procurement reflects principles of stabilizing clinical use, ensuring quality, preventing excessive competition, and avoiding collusion [5] - Group competition is structured to ensure continuity in clinical use, with products selected based on demand and supply capabilities, ensuring high clinical acceptance [5] - The selection rules have been refined to prevent underpricing, with a control benchmark set at 65% of the average price when the lowest bid is excessively low, impacting 8 out of 20 competitive groups [5] Group 4: Historical Context - Since 2020, the healthcare department has conducted six batches of national high-value medical consumables procurement, covering 9 categories and 142 types of medical consumables across major clinical fields [6]

Core Insights - The sixth batch of national organized high-value medical consumables centralized procurement was held in Tianjin, with 227 companies submitting bids for 496 products, resulting in 440 products from 202 companies being selected [1][2] Group 1: Procurement Details - The procurement included 12 types of medical consumables, specifically drug-coated balloons and urological intervention products, with a significant focus on mainstream companies to ensure diverse supply [1] - The bidding process lasted 11 hours, concluding with the announcement of selected companies the following day [1][2] - The procurement introduced a "reference price" mechanism to prevent irrational bidding and included multiple revival rules to enhance competition and selection rates [2] Group 2: Clinical Impact - Clinical experts indicated that the selected products will benefit patients undergoing related surgeries, particularly in urology and cardiovascular fields [1][3] - The urological intervention category included various essential products for treating urinary system stones, ensuring comprehensive coverage for surgical needs [3] - The centralized procurement aims to improve patient accessibility to treatments and reduce costs for established products, while also encouraging innovation among medical companies [3]

2026.01. 14 本文字数：1424，阅读时长大约2分钟 作者 | 第一财经 郭晋晖 封图 | 第六批耗材集采按规则二、规则三"复活"的报价环节。/郭晋晖摄 1月13日，第六批国家组织高值医用耗材集中带量采购（下称"集采"）在天津开标，下午18时20分， 经过两轮现场报价，用时11个小时的第六批国家组织高值医用耗材集采报价环节全部结束。 1月14日上午，国家组织高值医用耗材联合采购办公室发布拟中选结果，本次集采纳入药物涂层球 囊、泌尿介入两大类12种医用耗材，共有227家企业的496个产品投标，202家企业的440个产品中 选。医疗机构需求量大的主流企业积极中选，产品供应丰富多元。 多位临床医生对记者表示，这些集采品种落地之后将惠及相关手术患者。 药物涂层球囊又进一步细分为冠状动脉药物涂层球囊及外周血管药物涂层球囊，冠状动脉药物涂层球 囊是继心血管冠脉支架之后心血管领域的第二次集采。 企业代表投标/郭晋晖摄 公证员现场开启投标箱/郭晋晖摄 泌尿外科高值耗材是首次进入集采，泌尿介入类则具体细分到输尿管介入导丝、输尿管介入鞘、输尿 管球囊扩张导管、泌尿取石网篮、一次性输尿管软镜导管、肾造瘘套件六类耗材。 第 ...

Core Viewpoint - The sixth batch of high-value medical consumables procurement results has been announced, including 12 types of medical consumables in two categories, with 202 companies and 440 products successfully procured [1]. Group 1 - The procurement includes drug-coated balloons and urological intervention products, indicating a focus on high-demand medical supplies [1]. - A diverse range of products from mainstream companies that meet the needs of medical institutions has been selected, ensuring a rich supply [1]. - To date, the national medical insurance department has successfully procured 9 categories of 142 types of medical consumables, covering various clinical fields such as cardiology, orthopedics, peripheral vascular surgery, ophthalmology, otolaryngology, and urology [1]. Group 2 - Patients are expected to have access to the selected products from this procurement by around May 2026 [2].

Core Insights - The sixth batch of centralized procurement for high-value medical consumables was held in Tianjin, resulting in the selection of 440 products from 202 companies out of 496 bids from 227 companies, indicating a diverse supply of products to meet clinical needs [1][2] Group 1: Procurement Details - The procurement includes 12 types of medical consumables, specifically drug-coated balloons and urological intervention materials, which are crucial for treating vascular and urinary conditions [1] - All 42 products from 32 companies in the drug-coated balloon category were selected, ensuring a high match with clinical usage while reducing patient costs [1] - In the urological intervention category, 398 products from 170 companies were selected, addressing a previously unaddressed area in centralized procurement [1] Group 2: Policy Implementation - The procurement aligns with the central government's policy to optimize procurement processes, emphasizing stability in clinical use, quality assurance, and prevention of price undercutting [2] - Group competition was implemented to ensure continuity in clinical usage, with products selected based on demand and supply capabilities [2] - The selection rules were optimized to prevent price undercutting, with a benchmark set at 65% of the average price when the lowest bid is excessively low, impacting 8 out of 20 competitive groups [2] Group 3: Historical Context - Since 2020, the healthcare insurance department has conducted six batches of centralized procurement, successfully acquiring 142 types of medical consumables across various clinical fields, including cardiology, orthopedics, and urology [2]

Group 1 - The sixth batch of national organized high-value medical consumables procurement results has been announced, covering two major categories: drug-coated balloons and urological interventions, with 202 companies and 440 products successfully procured [2][4] - The procurement includes mainstream companies with high demand from medical institutions, ensuring a diverse supply of products [4] - To date, the national medical insurance department has successfully procured 9 categories and 142 types of medical consumables, involving various clinical fields such as cardiology, orthopedics, peripheral vascular, ophthalmology, otolaryngology, and urology [5] Group 2 - Patients are expected to use the products selected in this procurement by around May 2026 [5]

Core Insights - The sixth batch of high-value medical consumables procurement results has been announced, including 12 types of medical consumables in two categories: drug-coated balloons and urological interventions [1] - A total of 202 companies and 440 products have successfully been procured, with mainstream companies selected that have high demand from medical institutions, ensuring a diverse supply of products [1] - To date, the national medical insurance department has successfully procured 9 categories of 142 types of medical consumables, covering various clinical fields such as cardiology, orthopedics, peripheral vascular surgery, ophthalmology, otolaryngology, and urology [1] - Patients are expected to have access to the selected products from this procurement by around May 2026 [1]

Core Viewpoint - The sixth batch of centralized procurement for high-value medical consumables was opened for bidding in Tianjin, with results expected to be announced on January 14. This procurement aims to stabilize clinical practices, ensure quality, and prevent price undercutting in the industry [1]. Group 1: Procurement Details - The procurement includes 12 types of medical consumables, covering drug-coated balloons and urological intervention products. For instance, the annual demand for drug-coated balloons in medical institutions is approximately 610,000 units [1]. - The urological intervention consumables, which are used for kidney stones and ureteral stones, represent a previously unaddressed area in centralized procurement, with eight products included in this batch [1]. Group 2: Principles and Regulations - The procurement process is guided by principles aimed at stabilizing clinical practices, ensuring quality, preventing excessive competition, and avoiding price undercutting. This is the first time the term "preventing excessive competition" has been mentioned in the context of consumables [1]. - The National Healthcare Security Administration has set a procurement cycle of three years, during which medical institutions are required to prioritize the purchase and use of the selected products and ensure timely payments according to the procurement agreements [1].